For the year ending 2025-12-31, CLDX made $1,545K in revenue. -$258,445K in net income. Net profit margin of -16727.83%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenues | 1,545 | 13 | ||
| Research and development | 245,074 | 163,550 | ||
| General and administrative | 43,838 | 38,548 | ||
| Total operating expenses | 288,912 | 202,098 | ||
| Operating loss | -287,367 | -195,078 | ||
| Investment and other income, net | 28,610 | 37,215 | ||
| Net loss | -258,757 | -157,863 | ||
| Unrealized gain on marketable securities | 312 | 6 | ||
| Comprehensive loss | -258,445 | -157,857 | ||
| Basic EPS | -3.9 | -2.45 | ||
| Diluted EPS | -3.9 | -2.45 | ||
| Basic Average Shares | 66,422,000 | 64,395 | ||
| Diluted Average Shares | 66,422,000 | 64,395 | ||
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX)